Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  vemurafenib
Find trials that include:  Any drugs shown
Results 1-19 of 19 for your search:
Start Over
An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: GO28399, NCI-2013-01160, 2012-003144-80, NCT01739764
BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO27826, NCI-2012-03085, 2011-004011-24, G027826, NCT01667419
Leflunomide and Vemurafenib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-088, NCI-2014-00593, NCT01611675
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: P1446A-05/72/12, NCI-2013-02011, NCT01841463
Decitabine, Vemurafenib, and Cobimetinib in Treating Patients with Stage IV Melanoma Who Have a BRAF Mutation
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201304715, NCI-2014-00838, ML28604, NCT01876641
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC #16992, NCI-2012-01379, NCT01659151
Biomarkers in Predicting Response in Patients with Locally Advanced Thyroid Cancer Receiving Vemurafenib before Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0471, NCI-2012-02171, 00000363, NCT01709292
Vemurafenib in Treating Patients with Relapsed or Refractory Hairy Cell Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-200, NCI-2012-02170, NCT01711632
Vemurafenib in Treating Patients With Stage III-IV Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ML28305, NCI-2013-00664, 2012-1048, NCT01813214
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ML28897, NCI-2014-01811, NCT02091141
Cobimetinib and Vemurafenib in Treating Patients with Melanoma That Has Spread To the Brain
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 13-123, NCI-2015-00016, ML29155, NCT02230306
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 17
Trial IDs: NO25390, NCI-2012-00500, 2011-000874-67, NCT01519323
Vemurafenib with Sorafenib Tosylate or Crizotinib in Treating Patients with Advanced Malignancies with BRAF Mutations
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1183, NCI-2012-00217, NCT01531361
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GP28384, NCI-2012-01880, 2012-002738-35, NCT01656642
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients with Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0748, NCI-2013-00541, NCT01787500
Hydroxychloroquine and Vemurafenib in Treating Patients With Stage IV Melanoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 06613, NCI-2013-01350, 818066, NCT01897116
Vemurafenib and Recombinant Interferon alfa-2b in Treating Patients With Stage III-IV Melanoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-107, NCI-2013-01876, PRO13040314, NCT01943422
Vemurafenib in Treating Younger Patients with Recurrent or Refractory BRAFV600E-Mutant Brain Tumors
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 25
Trial IDs: CC #120819, NCI-2014-00387, 076373, 092093, 120819 (PNOC 002), PNOC-002, NCT01748149
Vemurafenib and Cobimetinib in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: J1517, NCI-2015-01387, CIR00013140, NCT02427893
Start Over